Resmetirom Imapact on Mash: An Overview of Previous Studies

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disorder .Resmetirom, a selective thyroid hormone receptor-β (THR-β) agonist, has shown results in reducing liver fat and improve metabolic parameters. This review summarizes about pharmacological, clinical, and analytical studies undergone in Resmetirom. The study shows that it lowers hepatic steatosis and improves lipid profiles. From this study, we can see that Resmetirom is a promising therapeutic agent in treatment of MASH.